Literature DB >> 19091371

Fate and distribution of pharmaceuticals in wastewater and sewage sludge of the conventional activated sludge (CAS) and advanced membrane bioreactor (MBR) treatment.

Jelena Radjenović1, Mira Petrović, Damià Barceló.   

Abstract

In this paper we report on the performances of full-scale conventional activated sludge (CAS) treatment and two pilot-scale membrane bioreactors (MBRs) in eliminating various pharmaceutically active compounds (PhACs) belonging to different therapeutic groups and with diverse physico-chemical properties. Both aqueous and solid phases were analysed for the presence of 31 pharmaceuticals included in the analytical method. The most ubiquitous contaminants in the sewage water were analgesics and anti-inflammatory drugs ibuprofen (14.6-31.3 microg/L) and acetaminophen (7.1-11.4 microg/L), antibiotic ofloxacin (0.89-31.7 microg/L), lipid regulators gemfibrozil (2.0-5.9 microg/L) and bezafibrate (1.9-29.8 microg/L), beta-blocker atenolol (0.84-2.8 microg/L), hypoglycaemic agent glibenclamide (0.12-15.9 microg/L) and a diuretic hydrochlorothiazide (2.3-4.8 microg/L). Also, several pharmaceuticals such as ibuprofen, ketoprofen, diclofenac, ofloxacin and azithromycin were detected in sewage sludge at concentrations up to 741.1, 336.3, 380.7, 454.7 and 299.6 ng/g dry weight. Two pilot-scale MBRs exhibited enhanced elimination of several pharmaceutical residues poorly removed by the CAS treatment (e.g., mefenamic acid, indomethacin, diclofenac, propyphenazone, pravastatin, gemfibrozil), whereas in some cases more stable operation of one of the MBR reactors at prolonged SRT proved to be detrimental for the elimination of some compounds (e.g., beta-blockers, ranitidine, famotidine, erythromycin). Moreover, the anti-epileptic drug carbamazepine and diuretic hydrochlorothiazide by-passed all three treatments investigated. Furthermore, sorption to sewage sludge in the MBRs as well as in the entire treatment line of a full-scale WWTP is discussed for the encountered analytes. Among the pharmaceuticals encountered in sewage sludge, sorption to sludge could be a relevant removal pathway only for several compounds (i.e., mefenamic acid, propranolol, and loratidine). Especially in the case of loratidine the experimentally determined sorption coefficients (Kds) were in the range 2214-3321 L/kg (mean). The results obtained for the solid phase indicated that MBR wastewater treatment yielding higher biodegradation rate could reduce the load of pollutants in the sludge. Also, the overall output load in the aqueous and solid phase of the investigated WWTP was calculated, indicating that none of the residual pharmaceuticals initially detected in the sewage sludge were degraded during the anaerobic digestion. Out of the 26 pharmaceutical residues passing through the WWTP, 20 were ultimately detected in the treated sludge that is further applied on farmland.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19091371     DOI: 10.1016/j.watres.2008.11.043

Source DB:  PubMed          Journal:  Water Res        ISSN: 0043-1354            Impact factor:   11.236


  66 in total

1.  Occurrence and distribution of selected pharmaceuticals and personal care products in aquatic environments: a comparative study of regions in China with different urbanization levels.

Authors:  Hong Chen; Xiaojuan Li; Saichang Zhu
Journal:  Environ Sci Pollut Res Int       Date:  2012-02-04       Impact factor: 4.223

2.  Aerobic inhibition assessment for anaerobic treatment effluent of antibiotic production wastewater.

Authors:  Zeynep Cetecioglu
Journal:  Environ Sci Pollut Res Int       Date:  2013-10-22       Impact factor: 4.223

3.  Oxidation of ofloxacin by Oxone/Co(2+): identification of reaction products and pathways.

Authors:  Yunqing Pi; Jinglan Feng; Jingyu Sun; Mengke Song; Jianhui Sun
Journal:  Environ Sci Pollut Res Int       Date:  2013-11-01       Impact factor: 4.223

4.  Photodegradation of gemfibrozil in aqueous solution under UV irradiation: kinetics, mechanism, toxicity, and degradation pathways.

Authors:  Jingshuai Ma; Wenying Lv; Ping Chen; Yida Lu; Fengliang Wang; Fuhua Li; Kun Yao; Guoguang Liu
Journal:  Environ Sci Pollut Res Int       Date:  2016-04-07       Impact factor: 4.223

5.  Two-year survey of specific hospital wastewater treatment and its impact on pharmaceutical discharges.

Authors:  Laure Wiest; Teofana Chonova; Alexandre Bergé; Robert Baudot; Frédérique Bessueille-Barbier; Linda Ayouni-Derouiche; Emmanuelle Vulliet
Journal:  Environ Sci Pollut Res Int       Date:  2017-07-17       Impact factor: 4.223

6.  A comparison between two full-scale MBR and CAS municipal wastewater treatment plants: techno-economic-environmental assessment.

Authors:  Giorgio Bertanza; Matteo Canato; Giuseppe Laera; Mentore Vaccari; Magdalena Svanström; Sara Heimersson
Journal:  Environ Sci Pollut Res Int       Date:  2017-06-06       Impact factor: 4.223

7.  Understanding the mechanisms of trace organic contaminant removal by high retention membrane bioreactors: a critical review.

Authors:  Muhammad B Asif; Ashley J Ansari; Shiao-Shing Chen; Long D Nghiem; William E Price; Faisal I Hai
Journal:  Environ Sci Pollut Res Int       Date:  2018-09-27       Impact factor: 4.223

8.  A new decentralized biological treatment process based on activated carbon targeting organic micropollutant removal from hospital wastewaters.

Authors:  Teresa Alvarino; Elena García-Sandá; Isabel Gutiérrez-Prada; Juan Lema; Francisco Omil; Sonia Suárez
Journal:  Environ Sci Pollut Res Int       Date:  2018-07-04       Impact factor: 4.223

Review 9.  Endocrine disruptors compounds, pharmaceuticals and personal care products in urban wastewater: implications for agricultural reuse and their removal by adsorption process.

Authors:  Mariangela Grassi; Luigi Rizzo; Anna Farina
Journal:  Environ Sci Pollut Res Int       Date:  2013-03-27       Impact factor: 4.223

10.  Pharmaceuticals in a temperate forest-water reuse system.

Authors:  Andrew D McEachran; Damian Shea; Elizabeth Guthrie Nichols
Journal:  Sci Total Environ       Date:  2017-01-08       Impact factor: 7.963

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.